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Succinic semialdehyde (4-HB) ( SSA ) Figure 1 Metabolic interrelations of gamma-aminobutyric acid (GABA) metabolism. GGSA = gamma-glutamate semialdehyde dehydrogenase. Heavy arrows indicate major direction of metabolism aldehyde ( Figure 1 ) to 4-hydroxybutyric acid, and the organic aciduria may be detected by routine organic acid analysis. Although its primary metabolic role is that of neurotransmitter in the central nervous system, GABA is by no means localized only in brain. GABA is found in other non-neural tissues, including pancreas and kidney (Erdo 1985) . GABA is produced from putrescine as well as glutamic acid, although the latter is the major source of GABA. Since GABA is converted to succinic acid, it is capable of supporting oxidative metabolism in neural and non-neural tissues. The role of GABA as a neurotransmitter as well as its role in mammalian non-neural tissue have been reviewed in detail (Iversen 1982; Johnston and Singer 1982; Erdo 1985) .
This review describes inherited disorders involving the metabolic pathway of GABA, and the metabolism of the GABA-containing dipeptide homocarnosine (see Table 1 ). The disorders discussed will include pyridoxine-dependent seizures (?GAD deficiency; McKusick 266100; EC 4.1.1.15); GABA-transaminase deficiency (McKusick 137150; EC 2.6.1.19); succinic semialdehyde dehydrogenase deficiency (McKusick 271980; EC 1.2.1.24), and homocarnosinosis associated with serum carnosinase deficiency (McKusick 236130; EC 3.4.13,3) . Clinical, metabolic, enzymatic and pertinent molecular aspects of these four disorders are presented. Pyridoxine-dependent seizures, an autosomal recessive disorder, may be an inherited disorder of GABA metabolism, but convincing enzymatic proof of this is lacking.
The clinical picture of typical (early-onset) pyridoxine-responsive seizures should be differentiated from the atypical (later-onset or onset beyond infancy) presentation (Coker 1992 ) (see Table 2 ). The seizures in all clinical forms are unresponsive to conventional anticonvulsant therapy but respond to pharmacological doses of pyridoxine (10-100rag/day) with a requirement for constant treatment (Table 2 ) Tanaka et al 1992) . Patients are not pyridoxine-deficient. GABA concentration in brain has been measured (post mortem) in one patient and CSF CoABA in another; values were low in both. No data are available on CSF homocarnosine concentrations. In one patient GABA concentrations in CSF increased and seizures resolved following institution of pyridoxine therapy. Glutamic acid decarboxylase (GAD), the enzyme responsible for GABA production, requires pyridoxal-5'-phosphate as cofactor for the decarboxylation reaction ( Figure 1 ). It has been widely assumed that patients with pyridoxine-responsive seizures have defective GAD activity due to abnormal cofactor binding. Yoshida and coworkers (1971) presented the only evidence that pyridoxinedependent seizures are associated with GAD deficiency. These investigators documented an abnormality of cofactor (pyridoxal-5'-phosphate) binding to apo-GAD in biopsied renal cortex from a patient with mental retardation and pyridoxinedependent seizures. Using uniformly 14C-radiolabelled glutamate, no evolution of 14CO2 was detected without added pyridoxal-5'-phosphate in the in vitro assay, but ~4CO2 evolution in the patient's kidney extract was stimulated above the control range when cofactor was added. These results are of interest, but may be inconclusive. Recent work has demonstrated different molecular forms of GAD (molecular weights 65 and 67 kDa, respectively) (Bu et al 1992) , and both GAD forms may be found in brain and pancreas (Baekkeskov et al 1990) . Abnormalities of the 65kDa form of GAD may be associated with insulin-dependent diabetes mellitus (IDDM) and stiffman syndrome, a rare neurological disease associated with IDDM (Baekkeskov et al 1990) . With respect to the findings of Yoshida and colleagues using kidney as the source of GAD for enzyme study, we do not know which molecular weight species The need for larger pyridoxine doses in some patients Higher incidence
Biochemical findings
Brain GABA (1 patient post mortem) and CSF GABA (1 patient) were low No data available on CSF homocarnosine concentrations Hypothesis: genetic defect at the pyridoxal phosphate coenzyme binding site of glutamic acid decarboxylase resulting in brain GABA deficiency
Treatment
Minimum effective daily dose: varies between 10 and 100rag orally Convulsions cease within a few minutes when parenterally administered, within a few hours when given orally Single dose effective for a consistent period (2 5 days) Interruption of treatment, seizures return In case of (suspected) intrauterine convulsions, treatment of mother with pyridoxine is effective (100 rag/day) of GAD was assayed in kidney extract, and it is possible that the enzyme results reflect contributions from one, or both, molecular weight species of GAD. Therefore, demonstration of a renal GAD defect may not necessarily imply a brain enzyme defect.
GABA-transaminase deficiency
GABA-transaminase deficiency has been reported in two Flemish siblings (male and female) who had severe psychomotor retardation, hypotonia, hyperreflexia, seizures and accelerated linear growth (Jaeken et al 1984) . Both died before 3 years of age. Autopsy findings revealed leukodystrophy in the brain of the male. Biochemical and enzymatic findings in GABA-transaminase deficiency are summarized in Table 3 . Free GABA and/Lalanine were elevated in plasma and CSF. Total GABA, unidentified GABA conjugates and homocarnosine were elevated in CSF. Elevated fasting plasma growth hormone (8-38 ng/ml, normal < 5) was consistent with the growth hormone-releasing effect of GABA, and was the likely cause of the increased linear growth in the two patients. GABA transaminase deficiency was documented in biopsied liver and leukocytes derived from the female ( Table 3 ). The (Gibson et al 1985) , so demonstration of deficiency in other tissues may suggest a defect in brain GABA transaminase. A diagnosis of GABA transaminase deficiency cannot be accomplished in cultured skin fibroblasts or amniocytes because these cells do not express the enzyme. GABA transaminase is present, however, in chorionic villus tissue (Sweetman et al 1986) . Molecular analysis of GABA transaminase deficiency has not been reported. However, a cDNA for GABA transaminase has been isolated from porcine brain, suggesting that a human brain cDNA should be isolated shortly (Kwon et al 1992) .
Succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria) Jakobs and coworkers (1981) identified the first case of 4-hydroxybutyric aciduria. To date, 32 cases have been identified, and thc clinical, mctabolic and enzymatic features for most patients are summarized in Table 4 . In succinic semialdehyde dehydrogenase deficiency the oxidative step is blocked, and accumulated succinic semialdehyde is reduced to 4-hydroxybutyric acid (7-hydroxybutyric acid) in a reaction catalysed by 4-hydroxybutyrate dehydrogenase (EC 1.1.1.61). Succinic semialdehyde dehydrogenase deficiency is an interesting inborn error of GABA metabolism because the biochemical hallmark, 4-hydroxybutyric acid, is a compound with unique neuropharmacological properties that have been summarized (Mamelak 1989) . It is noteworthy that 4-hydroxybutyric acid, much like GABA, has also been found in the non-neural tissues of animals (Mamelak 1989 ), but its role there is unclear. CEnzyme results from a total of 21 patients studied.
Range of residual activity

0-19% (mean 4%) 0-6% (mean 2%) 4-12% (mean 8%)
The clinical presentation of succinic semialdehyde dehydrogenase deficiency includes delayed intellectual, motor, speech and language development (Table 4) . Many patients manifest hypotonia and ataxia, but these and other clinical manifestations are variable. Ataxia, when present, may resolve with age (Hodson et al 1990) . The key feature of succinic semialdehyde dehydrogenase deficiency is accumulation of 4-hydroxybutyric acid in body fluids, including urine, plasma and CSF, but quantitation of this metabolite may be hampered by loss due to volatility. In the patients analysed thus far, there is a tendency toward age-dependent urinary excretion of 4-hydroxybutyric acid, with high concentrations in younger patients and lower concentrations in older patients, although this may be a reflection of the change in ratio between brain and body mass with age Jakobs et al 1990) . It is tempting to correlate age-dependent 4-hydroxybutyric acid excretion with the observation that some younger succinic semialdehyde dehydrogenase-deficient patients are hypoactive, while some older patients are hyperactive, and even aggressive. This raises the possibility that 4-hydroxybutyric acid may bind to inhibitory sites in brain at high concentration and excitatory sites at low concentration.
Other metabolites indicative of the fl-and e-oxidation of 4-hydroxybutyric acid may be variably detected in the urine of succinic semialdehyde dehydrogenasedeficient patients (Table 4, Figure 2 ). Dicarboxylic acids and 3-hydroxypropionic acid may be a source of diagnostic confusion by suggesting an abnormality of acylCoA or propionyl-CoA metabolism, but identification of 4-hydroxybutyric acid should establish the correct diagnosis. The explanation for glycinuria in some succinic semialdehyde dehydrogenase-deficient patients remains unclear. Glycolic acid in the urine of these patients is a product of the /?-oxidation of 4-hydroxybutyric acid, consistent with the finding that rat liver mitochondria produce glycolyl-CoA when incubated with 4-hydroxybutyric acid (Vamecq et al 1990) . Glycolic acid can be converted to glycine, and may be responsible for some increase of glycine in physiological fluids from succinic semialdehyde dehydrogenase-deficient patients.
Threo-and erythro-4,5-dihydroxyhexanoic acids (and the corresponding lactone forms) have been identified in the urine of succinic semialdehyde dehydrogenasedeficient patients (Brown et al 1987) (Table 4 ). This is of interest because 4,5-dihydroxyhexanoic acid (and its related forms) have not been identified in other heritable disorders of human metabolism, and these organic acids may be additional specific markers for succinic semialdehyde dehydrogenase deficiency, in addition to 4-hydroxybutyric acid. Brown and colleagues speculate that the dihydroxyhexanoic acid derivatives arise from condensation of a two-carbon moiety of pyruvate (Figure 2) . The identification of metabolites in the urine of succinic semialdehyde dehydrogenase-deficient patients related to pathways of fatty-acid, pyruvate, and glycine metabolism suggests that the deficiency has metabolic consequences beyond the pathway of GABA metabolism.
Succinic semialdehyde dehydrogenase deficiency is demonstrated in isolated and cultured leukocytes (Table 4) . Intermediate levels of enzyme activity for parents and family members of affected probands is consistent with autosomal recessive inheritance (Pattarelli et al 1988) . Consanguinity of 7 in 21 families with affected probands, and sex distribution for deficient patients (11 male: 16 female) are additional evidence of autosomal recessive inheritance. The prenatal diagnosis of an affected fetus with succinic semialdehyde dehydrogenase deficiency has been reported . 4-Hydroxybutyric acid was elevated in amniotic fluid, and succinic semialdehyde dehydrogenase activity was absent from cultured amniocytes and autopsied fetal brain, liver and kidney (Chambliss et al 1993) . The irreversible GABA-transaminase inhibitor 7-vinylGABA (vigabatrin) has shown promise as a therapy for succinic semialdehyde dehydrogenase-deficient patients, with improvement of cerebellar signs in 5 out of 6 patients receiving the drug Howells et al 1992) . However, long-term administration of vigabatrin should be monitored closely, because one of the metabolic consequences of administering this drug is increased GABA levels in the central nervous system. Succinic semialdehyde dehydrogenase deficiency can manifest a mild to severe neurological course. Some patients have died, despite the fact that there is no episodic metabolic decompensation or metabolic acidosis. Despite the phenotypic heterogeneity observed, all patients demonstrate comparable low levels of residual activity in isolated or cultured leukocytes, suggesting that insight into phenotypic heterogeneity may be gained through mutation analysis. Such studies await the isolation and characterization of mammalian cDNAs encoding succinic semialdehyde dehydrogenase, although cDNAs encoding the enzyme have been isolated from Escherichia coli (Marek and Henson 1988; Bartsch et al 1990) .
Homocarnosinosis
Homocarnosine is a brain-specific dipeptide of L-histidine and GABA whose physiological role is unknown (Skaper et al 1973) . Homocarnosinosis was identified in a Norwegian family, including the mother and three affected siblings from a total of four children (Sjaastad et al 1976) . Clinical manifestations in the affected siblings included spastic paraplegia, progressive mental deterioration and retinal pigmentation; the mother had no neurological findings. The disorder was characterized by homocarnosine accumulation in the CSF from the three patients and their mother (CSF homocarnosine concentration 50-75 mmol/L, normal < 3 mmol/L) (Sjaastad et al 1977) . CSF carnosine was not increased in the patients, but urinary excretion of carnosine was elevated (Lunde et al 1982) .
Homocarnosinase activity has not been convincingly demonstrated in normal human tissues (Lenney et al 1983) . Serum carnosinase deficiency has been documented in patients without accumulation of homocarnosine, and with variable neurological findings (Murphey et al 1973; Cohen et al 1985) . Carnosinase deficiency was, however, demonstrated in CSF from the three homocarnosinosis patients (Lenney et al 1983) . Although homocarnosinosis resembles serum carnosinase deficiency, homocarnosinosis would intuitively appear to be a different disorder because the three affected Norwegian patients did not accumulate carnosine in the CSF. Detailed biochemical studies in additional patients with homocarnosinosis may clarify the underlying biochemistry.
Cerebrospinal fluid and the identification of inherited defects of GABA metabolism
With the exception of succinic semialdehyde dehydrogenase deficiency, many of the inherited disorders of GABA metabolism are unlikely to be diagnosed without accurate investigation of CSF metabolites. Besides free GABA, several other forms of GABA occur in human CSF: GABA-peptides (mainly homocarnosine, GABAlysine and GABA-cystathionine), N-carboxyethylGABA and 2-pyrrolidinone. Of these, homocarnosine and 2-pyrrolidinone are quantitatively the most important. 2-Pyrrolidinone, the cyclization product of GABA, accounts for essentially all of the so-called 'unidentified conjugated GABA', i.e. the difference between total GABA and the sum of homocarnosine and free GABA. CSF GABA concentrations probably reflect brain GABA concentrations and are probably only minimally affected by alterations of the peripheral GABA concentration. Most methods for determining free GABA in brain tissue are insufficiently sensitive or specific for measuring the low free GABA concentrations in CSF. Two methods seem to have the required specificity and sensitivity: ion-exchange or reversed-phase chromatography with fluorescence detection (Carchon et al 1991) and (stable isotope dilution) gas chromatography-mass spectrometry (Kok et al 1993) . Furthermore, the determination of free GABA in CSF is difficult because: (1) fractional collection of CSF specimens demonstrates a gradient effect of GABA concentration, with low concentration in the first and high concentration in subsequent specimens, which limits valid comparison between patient and controls; and (2) free GABA concentration in CSF shows artefactual increases due to enzymatic hydrolysis of homocarnosine unless specimens are deep-frozen immediately after withdrawal (Carchon et al 1991) . At present it may be necessary to employ total GABA concentrations in CSF as a marker for alterations in brain GABA metabolism, but the possibility exists that patients with GABA-transaminase deficiency will be overlooked (Table 3) .
Literature data on lumbar CSF free GABA concentrations in control children are summarized in Carchon et al (1991) . Notably, children under 2 years of age have lower values than older children. The lower limit of lumbar CSF free GABA concentrations increases linearly from about 15nmol/L in the neonatal period to about 65 nmol/L at the age of 1 year, and remains stable from there on. A similar evolution during the first year of life in CSF homocarnosine levels (an increase from 2.5/~mol/L to 6 #tool/L) and CSF total GABA (an increase from 4/zmol/L to 7 #tool/L) has been reported .
CONCLUSIONS AND FUTURE DIRECTIONS
The study of patients with inherited disorders of GABA metabolism will provide new insight into biochemical and molecular aspects of GABA metabolism. Of the four diseases, the primary defect has been described convincingly only for succinic semialdehyde dehydrogenase and GABA-transaminase deficiencies, although documentation of deficient brain GABA-transaminase activity has yet to be presented. The underlying biochemistry of pyridoxine-dependent seizures and GAD deficiency, as well as homocarnosinosis, requires clarification. The multiple molecular forms of GAD pose a challenge to understanding which GAD protein is, or whether both are, involved in pyridoxinc-dependent seizures. The investigation of molecular aspects of succinic semialdehyde dehydrogenase and GABA-transaminase deficiencies should be accomplished when human cDNAs encoding these proteins are isolated and characterized.
The identification of future patients with certain defects of GABA metabolism will depend upon the availability of accurate methods for determining free GABA concentrations in CSF. We suggest that more general paediatricians and neurometabolic specialists should recommend free and total GABA determination in CSF from patients with unexplained neurological abnormalities.
